Drug Resistance Updates
Volume 12, Issue 4 , Pages 114-126 , August 2009

Understanding the causes of multidrug resistance in cancer: a comparison of doxorubicin and sunitinib

Received 9 June 2009 ,Revised 7 July 2009 ,Accepted 8 July 2009.

References 

  1. Abolhoda A, Wilson AE, Ross H, Danenberg PV, Burt M, Scotto K. Rapid activation of MDR1 gene expression in human metastatic sarcoma after in vivo exposure to doxorubicin. Clin. Cancer Res. 1999;5:3352–3356
  2. Abraham J, Bakke S, Rutt A, et al. A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma. Cancer. 2002;94:2333–2343
  3. Abraham J, Edgerly M, Wilson R, Chen C, Rutt A, Bakke S, et al. A phase I study of the P-glycoprotein antagonist Tariquidar in combination with vinorelbine. Clin. Cancer Res. 2009;15:3574–3582
  4. Abrams TJ, Murray LJ, Pesenti E, et al. Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with “standard of care” therapeutic agents for the treatment of breast cancer. Mol. Cancer Ther. 2003;2:1011–1021
  5. Abu Ajaj K, Kratz F. Development of dual-acting prodrugs for circumventing multidrug resistance. Bioorg. Med. Chem. Lett. 2009;19:995–1000
  6. Araujo RP, Liotta LA, Petricoin EF. Proteins, drug targets and the mechanisms they control: the simple truth about complex networks. Nat. Rev. Drug Discov. 2007;6:871–880
  7. Aroui S, Brahim S, de Waard M, Bréard J, Kenani A. Efficient induction of apoptosis by doxorubicin coupled to cell-penetrating peptides compared to unconjugated doxorubicin in the human breast cancer cell line MDA-MB 231. Cancer Lett. 2009;
  8. Ashworth A. Drug resistance caused by reversion mutation. Cancer Res. 2008;68:10021–10023
  9. Banerjee S, Wang Z, Kong D, Sarkar FH. 3,3′-diindolmethane enhances chemosensitivity of multiple chemotherapeutic agents in pancreatic cancer. Cancer Res. 2009;69:5592–5600
  10. Barré B, Vigneron A, Perkins N, Roninson IB, Gamelin E, Coqueret O. The STAT3 oncogene as a predictive marker of drug resistance. Trends Mol. Med. 2007;13:4–11
  11. Beck WT, Grogan TM, Willman CL, et al. Methods to detect P-glycoprotein-associated multidrug resistance in patients’ tumors: consensus recommendations. Cancer Res. 1996;56:3010–3020
  12. Bednarski BK, Ding X, Coombe K, Baldwin AS, Kim HJ. Active roles for inhibitory κB kinases α and β in nuclear factor-κB-mediated chemoresistance to doxorubicin. Mol. Cancer Ther. 2008;7:1827–1835
  13. Benavente S, Hunag S, Armstrong EA, Chi A, Hsu KT, Wheeler DL, et al. Establishment and characterization of a model of acquired resistance to epidermal growth factor receptor targeting agents in human cancer cells. Clin. Cancer Res. 2009;15:1585–1592
  14. Berns K, Horlings HM, Hennessy BT, et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell. 2007;12:395–402
  15. Biedler JL, Schrecker AW, Hutchison DJ. Selection of chromosomal variant in amethopterin-resistant sublines of leukemia L1210 with increased levels of dihydrofolate reductase. J. Natl. Cancer Inst. 1963;31:575–601
  16. Bhatt RS. Mechanisms of Resistance to Anti-Angiogenic Therapy. Am. Assoc. Cancer Res. Lecture Denver (Co); 2009;
  17. Bhatt RS, Wang X, Zhang L, et al. Cox-2 inhibition delays resistance to sunitinib in RCC xenograft models. In: Proc. of the 100th Ann. Meeting Am. Assoc. Cancer Res. 2009 April 18–22, Denver, CO/Philadelphia (PA). 2009;Abstract nr 153
  18. Borst, P., 1961. Een biochemisch onderzoek over mitochondriën geïsoleerd uit een ascites tumor. M.D. Thesis, Jacob van Campen, Amsterdam.
  19. Borst P. Interrelations between cytoplasmic and mitochondrial diphosphopyridine nucleotide in Ehrlich ascites tumor cells. In: Proc. 5th Intern. Congr. Biochem., vol. II. Pergamon Press, London. 1963;p. 233–247
  20. Borst P, Rottenberg S. Cancer cell death by programmed necrosis?. Drug Resist. Updates. 2004;7:321–324
  21. Borst P, Rottenberg S, Jonkers J. How do real tumors become resistant to cisplatin?. Cell Cycle. 2008;7:1353–1359
  22. Broxterman HJ, Georgopapadakou NH. Anticancer therapeutics: a surge of new developments increasingly target tumor and stroma. Drug Resist. Updates. 2007;10:182–193
  23. Broxterman HJ, Lankelma J, Hoekman K. Resistance to cytotoxic and anti-angiogenic agents: similarities and differences. Drug Resist. Updates. 2003;6:111–127
  24. Broxterman HJ, Lankelma J, Pinedo HM. How to probe clinical tumour samples for P-glycoprotein and multidrug resistance-associated protein. Eur. J. Cancer. 1996;32A:1024–1033
  25. Broxterman HJ, Lankelma J, Pinedo HM, Eekman CA, Währer DCR, Ossenkoppele GJ, et al. Theoretical and practical consideration for the measurement of P-glycoprotein function in acute myeloid leukemia. Leukemia. 1997;11:1110–1118
  26. Broxterman HJ, Pinedo HM. Energy metabolism in multidrug resistant tumor cells: a review. J. Cell. Pharmacol. 1991;2:239–247
  27. Broxterman HJ, Pinedo HM, Kuiper CM, Schuurhuis GJ, Lankelma J. Glycolysis in P-glycoprotein-overexpressing human tumor cell lines. Effects of resistance-modifying agents. FEBS Lett. 1989;247:405–410
  28. Broxterman HJ, Schuurhuis GJ, Lankelma J, et al. Highly sensitive and specific detection of P-glycoprotein function for haematological and solid tumour cells using a novel nucleic acid stain. Br. J. Cancer. 1997;76:1029–1034
  29. Broxterman HJ, Sonneveld P, Pieters R, et al. Do P-glycoprotein and major vault protein (MVP/LRP) expression correlate with in vitro daunorubicin resistance in acute myeloid leukemia?. Leukemia. 1999;13:258–265
  30. Bourguignon LYW, Xia W, Wong G. Hyaluronan-mediated CD44 interaction with p300 and SIRT1 regulates β-catenin signaling and NFκB-specific transcription activity leading to MDR1 and Bcl-XL gene expression and chemoresistance in breast tumor cells. J. Biol. Chem. 2009;284:2657–2671
  31. Bousquet G, Varna M, El Bouchtaoui M, et al. In vitro and in vivo phenotypic and genotypic characterizations of breast, liver and renal cancer models mimicking human resistance to sunitinib. In: Proc. of the 100th Ann. Meeting Am. Assoc. Cancer Res.. 2009 April 18–22, Denver, CO/Philadelphia (PA). 2009;Abstract nr 151
  32. Bouzin C, Feron O. Targeting tumor stroma and exploiting mature tumor vasculature to improve anti-cancer drug delivery. Drug Resist. Updates. 2007;10:109–120
  33. Büchner T, Berdel WE, Haferlach C, et al. Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German acute myeloid leukemia cooperative group. J. Clin. Oncol. 2009;27:61–69
  34. Burchert A. Roots of imatinib resistance: a question of self-renewal?. Drug Resist. Updates. 2007;10:152–161
  35. Burkitt K, Chun SY, Dang DT, Dang LH. Targeting both HIF-1 and HIF-2 in human colon cancer cells improves tumor response to sunitinib treatment. Mol. Cancer Ther. 2009;8:1148–1156
  36. Cao Y, Zhong W, Sun Y. Improvement of antiangiogenic therapy by understanding the mechanisms of antiangiogenic factor interplay and drug resistance. Semin. Cancer Biol. 2009;
  37. Castillo-Ávila W, Piulats JM, Garcia del Muro X, et al. Sunitinib inhibits tumor growth and synergizes with cisplatin in orthotopic models of cisplatin-sensitive and cisplatin-resistant human testicular germ cell tumors. Clin. Cancer Res. 2009;15:3384–3395
  38. Chan DA, Kawahara TLA, Sutphin PD, Chang HY, Chi JT, Giaccia AJ. Tumor vasculature is regulated by PHD2-mediated angiogenis and bone-marrow-derived cell recruitment. Cancer Cell. 2009;15:527–538
  39. Chang DK, Chiu CY, Kuo SY, et al. Antiangiogenic targeting liposomes increase therapeutic efficacy for solid tumors. J. Biol. Chem. 2009;284:12905–12916
  40. Chen N, Chen X, Hunag R, et al. BCL-xL is a target gene regulated by hypoxia-inducible factor-1α. J. Biol. Chem. 2009;284:10004–10012
  41. Chen J, Kobayashi M, Darmanin S, et al. Pim-1 plays a pivotal role in hypoxia-induced chemoresistance. Oncogene. 2009;
  42. Chen J, Kobayashi M, Darmamin S, et al. Hypoxia-mediated upregulation of Pim-1 contributes to solid tumor formation. Am. J. Pathol. 2009;175:
  43. Choi JH, Sheu JJ, Guan B, et al. Functional analysis of 11q13, 5 amplicon identifies RSf-1 (HBXAP) as a gene involved in paclitaxel resistance in ovarian cancer. Cancer Res. 2009;69:1407–1415
  44. Chu TF, Rupnick MA, Kerkela R, et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet. 2007;370:2011–2019
  45. Cools J, Maertens C, Marynen P. Resistance to tyrosine kinase inhibitors: calling on extra forces. Drug Resist. Updates. 2005;8:119–176
  46. Crawford Y, Kasman I, Yu L, Zhong C, Wu X, Modrusan Z, et al. PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumor refractory to anti-VEGF treatment. Cancer Cell. 2009;15:21–34
  47. Crijns APG, Fehrmann RS, de Jong S, et al. Survival-related profile, pathways, and transcription factors in ovarian cancer. PLOS med. 2009;6:e10000024
  48. Czabanka M, Vinci M, Heppner F, Ullrich A, Vajkoczy P. Effects of sunitinib on tumor hemodynamics and delivery of chemotherapy. Int. J. Cancer. 2009;124:1293–1300
  49. Dai CL, Liang YJ, Wang YS, et al. Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent sunitinib was associated with inhibiting the function of ABCG2. Cancer Lett. 2009;279:74–83
  50. Danø K. Active outward transport of daunomycin in resistant Ehrlich ascites tumor cells. Biochem. Biophys. Acta. 1973;323:466–483
  51. Dent P, Curiel DT, Fisher PB, Grant S. Synergistic combinations of signaling pathway inhibitors: mechanisms for improved cancer therapy. Drug Resist. Updates. 2009;12:65–73
  52. DePrimo SE, Bello CL, Smeraglia J. Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins. J. Transl. Med. 2007;5:32
  53. De Visser KE, Jonkers J. Towards understanding the role of cancer-associated inflammation in chemoresistance. Curr. Pharmaceut. Des. 2009;15:1844–1853
  54. Di Michele M, Della Corte A, Cicchillitti L, et al. A proteomic approach to paclitaxel chemoresistance in ovarian cancer cell lines. Biochim. Biophys. Acta. 2009;1794:225–236
  55. Du G, Lin H, Wang M, et al. Quercetin greatly improved therapeutic index of doxorubicin against 4T1 breast cancer by its opposing effects on HIF-1α in tumor and normal cells. Cancer Chemother. Pharmacol. 2009;
  56. Duyndam MC, van Berkel MP, Dorsman JC, Rockx DA, Pinedo HM, Boven E. Cisplatin and doxorubicin repress vascular endothelial growth factor expression and differentially down-regulate hypoxia-inducible factor 1 in human ovarian cancer cells. Biochem. Pharmacol. 2007;74:191–201
  57. Eichhorn PJA, Gili M, Scaltriti M, et al. Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235. Cancer Res. 2008;68:9221–9230
  58. ElBayoumi TA, Torchilin VP. Tumor-targeted nanomedicines: enhanced antitumor efficacy in vivo of doxorubicin-loaded, long-circulating liposomes modified with cancer-specifc monoclonal antibody. Clin. Cancer Res. 2009;15:1973–1980
  59. Elliott AM, Al-Hajj MA. ABCB8 mediates doxorubicin resistance in melanoma by protecting the mitochondrial genome. Mol. Cancer Res. 2009;7:79–87
  60. Etemadmoghadam D, de Fazio A, Beroukhim R, et al. Integrated genome-wide DNA copy number and expression analysis identifies distinct mechanisms of primary chemoresistance in ovarian carcinomas. Clin. Cancer Res. 2009;15:1417–1427
  61. Fabian MA, Bigg WH, Treiber DK, et al. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat. Biotechnol. 2005;23:329–336
  62. Farmer P, Bonnefoi H, Anderle P, et al. A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer. Nat. Med. 2009;15:68–74
  63. Feller N, Hoekman K, Kuiper CM, et al. A patient with adrenocortical carcinoma: characterization of its biological activity and drug resistance profile. Clin. Cancer Res. 1997;3:389–394
  64. Fernandez HF, Sun Z, Litzow MR, et al. A randomized trial of anthracycline dose intensification during induction of younger patients with acute myeloid leukemia: Results of Eastern Cooperative Oncology Group study E1900. 2009 ASCO Annual Meeting. J. Clin. Oncol. 2009;27:15s;(suppl; Abstract # 7003)
  65. Fojo T. Commentary: novel therapies for cancer: why dirty might be better. The Oncologist. 2008;13:277–283
  66. Fojo T. Multiple paths to a drug resistance phenotype: mutations, translocations, deletions and amplification of coding genes or promoter regions, epigenetic changes and microRNAs. Drug Resist. Updates. 2007;10:59–67
  67. Fojo T, Menefee M. Mechanisms of multidrug resistance: the potential role of microtubule-stabilizing agents. Ann. Oncol. 2007;18(Suppl. 5):v3–v8
  68. Folkman J. Angiogenesis, an organizing principle in drug discovery. Nat. Rev. Drug Discov. 2007;6:273–286
  69. Fong GH. Mechanisms of adaptive angiogenesis to tissue hypoxia. Angiogenesis. 2008;11:121–140
  70. Fong PC, Boss DS, Yap TA, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. New Engl. J. Med. 2009;361
  71. Force T, Kerkelä R. Cardiotoxicity of the new cancer therapeutics—mechanisms of, and approaches to, the problem. Drug Discov. Today. 2008;13:778–784
  72. Frieboes HB, Edgerton ME, Fruehauf JP, et al. Prediction of drug response in breast cancer using integrative experimental/computational modeling. Cancer Res. 2009;69:4484–4492
  73. Friedrich J, Seidel C, Ebner R, Kunz-Schughart LA. Spheroid-based drug screen: considerations and practical approach. Nat. Protocols. 2009;4:309–324
  74. Gajiwala KS, Wu JC, Christensen J, et al. KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients. Proc. Natl. Acad. Sci. 2009;106:1542–1547
  75. Gatenby RA, Silva AS, Gillies RJ, Frieden BR. Adaptive therapy. Cancer Res. 2009;69:4894–4903
  76. Ghajar CM, Meier R, Bissell MJ. Quis custodiet ipsos custodies. Who watches the watchmen?. Am. J. Pathol. 2009;174:1996–1999
  77. Gotink KJ, Rudek MA, Broxterman HJ, et al. The anitangiogenic tyrosine kinase inhibitor sunitinb has direct antitumor activity on renal and colorectal cancer cells in vitro at intratumoral concentrations achieved in mice. In: Proc. of the 100th Ann. Meeting Am. Assoc. Cancer Res.. 2009 April 18–22, Denver, CO/Philadelphia (PA). 2009;Abstract nr. 150
  78. Gottesman MM, Ling V. The molecular basis of multidrug resistance in cancer: the early years of P-glycoprotein research. FEBS Lett. 2006;580:998–1009
  79. Graeber TG, Osmanian C, Jacks T, Housman DE, Lowe SW, Giaccia AJ. Hypoxia-mediated selection of cells with diminished apoptotic potential. Nature. 1996;379:88–91
  80. Gu L, Tsark WM, Brown DA, Blanchard S, Synold TW, Kane SE. A new model for studying tissue-specifc mdr1a gene expression in vivo by live imaging. Proc. Natl. Acad. Sci. U.S.A. 2009;106:5394–5399
  81. Gutman D, Morales AA, Boise LH. Acquisition of a multidrug-resistant phenotype with a proteasome inhibitor in multiple myeloma. Leukemia. 2009;
  82. Hait WN. Targeted cancer therapeutics. Cancer Res. 2009;69:1263–1266
  83. Hambley TW. Is anticancer drug development heading in the right direction?. Cancer Res. 2009;69:1259–1262
  84. Harper ME, Antoniou A, Villalobos-Menuey E, et al. Characterization of a novel metabolic strategy used by drug-resistant tumor cells. FASEB J. 2002;16:1550–1557
  85. Hasinoff BB, Patel D, O’Hara KA. Mechanisms of myocyte cytotoxicity by the multiple receptor kinase inhibitor sunitinib. Mol. Pharmacol. 2008;74:1722–1728
  86. Hatziieremia S, Jordanides NE, Holyoake TL, Mountford JC, Jørgensen HG. Inhibition of MDR1 does not sensitize primitive chronic myeloid leukemia CD34+ cells to imatinib. Exp. Hematol. 2009;37:692–700
  87. Hauswald S, Duque-Afonso J, Wagner MM, et al. Histone deacetylase inhibitors induce a very broad, pleiotropic anticancer drug resistance phenotype in acute myeloid leukemia cells by modulation of multiple ABC transporter genes. Clin. Cancer Res. 2009;15:3705–3715
  88. Haznedar JŐ, Patyna S, Bello CL, et al. Single- and multiple-dose disposition kinetics of sunitinib malate, a multitargeted receptor tyrosine kinase inhibitor: comparative plasma kinetics in non-clinical species. Cancer Chemother. Pharmacol. 2009;
  89. Hirayama A, Kami K, Sugimoto M, et al. Quantitative metabolome profiling of colon and stomach cancer microenvironment by capillary electrophoresis time-of-flight mass spectrometry. Cancer Res. 2009;69:4918–4925
  90. Hosaka T, Kimura H, Heishi T, et al. Vasohibin-1 expression in endothelium of tumor blood vessels regulates angiogenesis. Am. J. Pathol. 2009;175:
  91. Hu S, Chen Z, Franke R, et al. Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transporters. In: Proc. Meeting Am. Assoc. Cancer Res.. 2009 April 18–22, Denver, CO/Philadelphia (PA): AACR. 2009;Abstract # 918
  92. Hui RC, Francis RE, Guest SK, et al. Doxorubicin activates FOXO3a to induce the expression of multidrug resistance gene ABCB1 (MDR1) in K562 leukemic cells. Mol. Cancer Ther. 2008;7:670–678
  93. Hulleman E, Kazemier KM, Holleman A, et al. Inhibition of glycolysis modulates prednisolone resistance in acute lymphoblastic leukemia cells. Blood. 2009;113:2014–2021
  94. Jandial DD, Farshchi-Heydari S, Larson CA, Elliott GI, Wrasidlo WJ, Howell SB. Enhanced delivery of cisplatin to intraperitoneal ovarian carcinomas mediated by the effects of bortezomib on the human copper transporter 1. Clin. Cancer Res. 2009;15:553–560
  95. Jiang BH, Liu LZ. Role of mTOR in anticancer drug resistance: perspectives for improved drug treatment. Drug Resist. Updates. 2008;11:63–76
  96. Kessel D, Botterill V, Wodinsky I. Uptake and retention of daunomycin by leukemic cells as factors in drug response. Cancer Res. 1968;28:938–941
  97. Kim WY, Oh SH, Woo JK, Hong WK, Lee HY. Targeting heat shock protein 90 overrides the resistance of lung cancer cells by blocking radiation-induced stabilization of hypoxia-inducible factor 1α. Cancer Res. 2009;69:1624–1632
  98. Kleespies A, Jauch KW, Bruns CJ. Tyrosine kinase inhibitors and gemcitabine: new treatment options in pancreatic cancer?. Drug Resist. Updates. 2006;9:1–18
  99. Klingbeil P, Marhaba R, Jung T, Kirmse R, Ludwig T, Zöller M. CD44 variant isoforms promote metastasis formation by a tumor cell–matrix cross-talk that supports adhesion and apoptosis resistance. Mol. Cancer Res. 2009;7:168–179
  100. Kopetz S, Lesslie DP, Dallas NA, et al. Synergistic activity of the Scr family kinase inhibitor dasatinib and oxaliplatin in colon carcinoma cells is mediated by oxidative stress. Cancer Res. 2009;69:3842–3849
  101. Kortylewski M, Xin H, Kujawski M, et al. Regulation of the IL-23 and IL-12 balance by STAT3 signaling in the tumor microenvironment. Cancer Cell. 2009;15:114–123
  102. Kroemer G. Mitochondria in cancer. Oncogene. 2006;25:4630–4632
  103. Kroemer G, Pouyssegur J. Tumor cell metabolism: cancer's Achilles heel. Cell. 2008;13:472–482
  104. Kujawski M, Kortylewski M, Lee H, Kay H, Yu H. Stat3 mediates cell-dependent tumor angiogenesis in mice. J. Clin. Invest. 2008;118:3367–3377
  105. Lal D, Murphy M, Prey J, Fetterly GJ, Wang ES. VEGF-Trap (Aflibercept) improves systemic delivery of doxorubicin to marrow and extramedullary sites in a preclinical model. In: Proc. of the 100th Ann. Meeting Am. Assoc. Cancer Res.. 2009 April 18–22, Denver, CO/Philadelphia (PA). 2009;Abstract nr 2003
  106. Lankelma J, Dekker H, Fernández-Luque FR, et al. Doxorubicin gradients in human breast cancer. Clin. Cancer Res. 1999;5:1703–1707
  107. Lankelma J, Fernández-Luque R, Dekker H, Pinedo HM. Simulation model of doxorubicin activity in islets of human breast cancer cells. Biochim. Biophys. Acta. 2003;1622:169–178
  108. Lau CK, Yang ZF, Ho DW, et al. An Akt/hypoxia-inducible factor-1α/platelet-derived growth factor-BB autocrine loop mediates hypoxia-induced chemoresistance in liver cancer cells and tumorigenic hepatic progenitor cells. Clin. Cancer Res. 2009;15:3462–3471
  109. Lee JO, Lee KW, Kim CJ, et al. Metastatic adrenocortical carcinoma treated with sunitinib: a case report. Jpn. J. Clin. Oncol. 2009;39:183–185
  110. Lee TY, Muschal S, Pravda EA, Folkman J, Abdollahi A, Javaherian K. Angiostatin regulates the expression of antiangiogenic and pro-apoptotic pathways via targeted inhibition of mitochondrial proteins. Blood. 2009;doi:10.10.1182/blood-2008-12-197236
  111. Lee K, Qian DZ, Rey S, Wei H, Liu JO, Semenza GL. Anthracy-cline chemotherapy inhibits HIF-1 transcriptional activity and tumor-induced mobilization of circulating angiogenic cells. Proc. Natl. Acad. Sci. U.S.A. 2009;106:2353–2358
  112. Le Tourneau C, Vidal L, Siu LL. Progress and challenges in the identification of biomarkers for EGFR and VEGFR targeting anticancer agents. Drug Resist. Updates. 2008;11:99–109
  113. Li JL, Sainson RC, Ein Oon C, et al. Interaction of VEGF and Notch pathways in tumor angiogenesis: DLL4 contributes to tumor resistance to anti-VEGF therapy in preclinical models. New drug combinations to target the Warburg effect in cancer therapy. In: Proc. of the 100th Ann. Meeting Am. Assoc. Cancer Res.. 2009 April 18–22, Denver, CO/Philadelphia (PA). 2009;Abstract nr 1998
  114. Li Y, Zhang T, Schwartz SJ, Sun D. New developments in HSP90 inhibitors as anti-cancer therapeutics: mechanisms, clinical perspective and more potential. Drug Resist. Updates. 2009;12:17–27
  115. Li QQ, Xu JD, Wang WJ, et al. Twist1-mediated adriamycin-induced eptithelial-mesenchymal transition relates to multidrug resistance and invasive potential in breast cancer cells. Clin. Cancer Res. 2009;15:2657–2665
  116. Linardou H, Dahabreh IJ, Kanaloupiti D, et al. Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small cell lung cancer and metastatic colorectal cancer. Lancet Oncol. 2008;9:962–972
  117. Liu F, Wang P, Jiang X, Tan G, Qiao H, Jiang H, et al. Antisense hypoxia-inducible factor 1α gene therapy enhances the therapeutic efficacy of doxorubicin to combat hepatocellular carcinoma. Cancer Sci. 2008;99:2055–2061
  118. Loges S, Schmidt T, Carmeliet P. “Anti-myeloangiogenic” therapy for cancer by inhibiting PlGF. Clin. Cancer Res. 2009;15:3648–3653
  119. LoPiccolo J, Blumenthal GM, Bernstein WB, Dennis PA. Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. Drug Resist. Updates. 2008;11:32–50
  120. Lu CW, Lin SC, Chen KF, Lai YY, Tsai SJ. Induction of pyruvate dehydrogenase kinase-3 by hypoxia-inducible factor-1 promotes metabolic switch and drug resistance. J. Biol. Chem. 2008;283:28106–28114
  121. Lü S, Yang J, Song X, et al. Point mutation of the proteasome β5 subunit gene is an important mechanism of bortezomib resistance in bortezomib-selected variant of Jurkat T cell lymphoblastic lymphoma/leukemia line. J. Pharmacol. Exp. Ther. 2008;326:423–431
  122. Lu J, Kovach JS, Johnson F, Chiang J, Hodes R, Lonser R, et al. Inhibition of serine/threonine phosphatase PP2A enhances cancer chemotherapy by blocking DNA damage induced defense mechanisms. Proc. Natl. Acad. Sci. U.S.A. 2009;
  123. Madhankumar AB, Slagle-Webb , Wang X, et al. Efficacy of interleukin-13 receptor-targeted liposomal doxorubicin in the intracranial brain tumor model. Mol. Cancer Ther. 2009;8:648–654
  124. Mahalingam D, Medina E, Swords RT, et al. Effect of sunitinib on TRAIL-induced apoptosis in preclinical colon cancer models. 2009 ASCO Annual Meeting. J. Clin. Oncol. 2009;27:(suppl; Abstract # e14633)
  125. Mansilla S, Bataller M, Portugal J. A nuclear bussing mechanism in transiently arrested cells generates drug-sensitive and drug-resistant cells. Biochem. Pharmacol. 2009;78:123–132
  126. Mayer RJ. Targeted therapy for advanced colorectal cancer-more is not always better. New Engl. J. Med. 2009;360:623–625
  127. McConkey DJ, Zhu K. Mechanisms of proteasome inhibitor action and resistance in cancer. Drug Resist. Updates. 2008;11:164–179
  128. McDermott U, Ames RY, Iafrate AJ, et al. Ligand-dependent platelet-derived growth factor receptor (PDGFR)-α activation sensitizes rare lung cancer and sarcoma cells to PDGFR kinase inhibitors. Cancer Res. 2009;69:3937–3946
  129. Meng RD, Shelton CC, Li YM, et al. γ-Secretase inhibitors abrogate oxaliplatin-induced activation of the Notch-1 signaling pathway in colon cancer cells resulting in enhanced chemosensitivity. Cancer Res. 2009;69:573–582
  130. Mirski SE, Gerlach JH, Cole SP. Multidrug resistance in a human small cell lung cancer line selected with Adriamycin. Cancer Res. 1987;47:2594–2598
  131. Michaelis M, Rothweiler F, Klassert D, von Deimling A, Weber K, et al. Reversal of P-glycoprotein-mediated multidrug resistance by the murine double minute 2 antagonist Nutlin-3. Cancer Res. 2009;69:416–421
  132. Middelburg R, de Haas RR, Dekker H, et al. Induction of p53 upregulated modulator of apoptosis messenger RNA by chemotherapeutic treatment of locally advanced breast cancer. Clin. Cancer Res. 2005;11:1863–1869
  133. Milani M, Harris AL. Targeting tumour hypoxia in breast cancer. Eur. J. Cancer. 2008;44:2766–2773
  134. Montemurro M, Schöffski P, Reichardt P, et al. Nilotinib in the treatment of advanced gastrointestinal stromal tumours resistant to both imantinib and sunitinib. Eur. J. Cancer. 2009;
  135. Mony U, Jawad M, Seedhouse C, Russell N, Pallis M. Resistance to FLT3 inhibition in an in vitro model of primary AML cells with a stem cell phenotype in a defined microenvironment. Leukemia. 2008;22:1395–1401
  136. Morin PJ. Drug resistance and the microenvironment: nature and nurture. Drug Resist. Updates. 2003;6:169–172
  137. Nahimana A, Attinger A, Aubry D, et al. The NAD inhibitor APO866 has potent antitumor activity against hematologic malignancies. Blood. 2009;113:3276–3286
  138. Nefedova Y, Gabrilovich D. Mechanisms and clinical prospects of Notch inhibitors in the therapy of hematological malignancies. Drug Resist. Updates. 2008;11:210–218
  139. Noguchi K, Kawahara H, Kaji A, Katayama K, Mitsuhashi J, Sugimoto Y. Substrate-dependent bidirectional modulation of P-glycoprotein-mediated drug resistance by erlotinib. Cancer Science. 2009;
  140. Niu G, Briggs J, Deng J, et al. Signal transducer and activator of transcription 3 is required for hypoxia-inducible factor-1 alpha RNA expression in both tumor and tumor-associated myeloid cells. Mol. Cancer Res. 2008;6:1099–1105
  141. Oerlemans R, Franke NE, Assaraf YG, et al. Molecular basis of bortezomib resistance: proteasome subunit β5 (PSMB5) gene mutation and overexpression of PSMB5 protein. Blood. 2008;112:2489–2499
  142. Olive KP, Jacobetz MA, Davidson CJ, et al. Inhibition of hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science. 2009;324:1457–1461
  143. Oyama M, Kozuka-Hata H, Tasaki S, et al. Temporal perturbation of tyrosine-phosphoproteome dynamics reveals the system-wide regulatory networks. Mol. Cell. Prot. 2009;8:226–231
  144. Pajic, M., Iyer, J.K., Kersbergen, A., et al., in press. A moderate increase in Mdr1a//1b expression causes in vivo resistance to doxorubicin in a mouse model for hereditary breast cancer. Cancer Res. 69.
  145. Palmowski M, Huppert J, Hauff P, et al. Vessel fractions in tumor xenografts depicted by flow- or contrast-sensitive three-dimensional high-frequency doppler ultrasound respond differently to antiangiogenic treatment. Cancer Res. 2008;68:7042–7049
  146. Park CY, Tseng D, Weismann IL. Cancer stem cell-directed therapies: recent data from the laboratory and clinic. Mol. Ther. 2009;17:219–230
  147. Peeters M, Price T, Van Laethem JL. Anti-epidermal growth factor receptor monotherapy in the treatment of metastatic colorectal cancer: where are we today?. The Oncologist. 2009;14:29–39
  148. Pelicano H, Martin DS, Xu RH, Hunag P. Glycolysis inhibition for anticancer treatment. Oncogene. 2006;25:4633–4646
  149. Pencreach E, Guérin E, Nicolet C, et al. Marked activity of irinotecan and rapamycin combination toward colon cancer cells in vivo and in vitro is mediated through cooperative modulation of the mammalian target of rapamycin/hypoxia-inducible factor-1α axis. Clin. Cancer Res. 2009;15:1297–1307
  150. Phng LK, Gerhardt H. Angiogenesis: a team effort coordinate by Notch. Dev. Cell. 2009;16:196–208
  151. Pichot CS, Hartig SM, Xia L, et al. Dasatinib synergizes with doxorubicin to Block growth, migration, and invasion of breast cancer cells. Br. J. Cancer. 2009;
  152. Potti A, Dressman HK, Bild A, et al. Genomic signatures to guide the use of chemotherapeutics. Nat. Med. 2006;12:1294–1300
  153. Rapisarda A, Melillo G. Role of the hypoxic tumor microenvironment in the resistance to anti-angiogenic therapies. Drug Resist. Updates. 2009;12:74–80
  154. Ravi R, Bedi A. NF-κB in cancer—a friend turned foe. Drug Resist. Updates. 2004;7:53–67
  155. Real PJ, Tosello V, Palomero T, et al. γ-secretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemia. Nat. Med. 2009;15:50–58
  156. Riedel RF, Porrello A, Pontzer E, et al. A genomic approach to identify molecular pathways associated with chemotherapy resistance. Mol. Cancer Ther. 2008;7:3141–3149
  157. Richardson A, Kaye SB. Drug resistance in ovarian cancer: the emerging importance of gene transcription and spatio-temporal regulation of resistance. Drug Resist. Updates. 2005;8:311–321
  158. Rixe O, Fojo T. Is cell death a critical end point for anticancer therapies or is cytostasis sufficient?. Clin. Cancer Res. 2007;13:7280–7287
  159. Rizzo P, Osipo C, Foreman K, Golde T, Osborne B, Miele L. Rational targeting of Notch signaling in cancer. Oncogene. 2008;27:5124–5131
  160. Robey RB, Hay N. Mitochondrial hexokinases, novel mediators of the antiapoptotic effects of growth factors and Akt. Oncogene. 2006;25:4683–4696
  161. Robey RB, Hay N. Is Akt the “Warburg kinase”?-Akt-energy metabolism interactions and oncogenesis. Semin. Cancer Biol. 2009;19:25–31
  162. Robey RW, To KK, Polgar O, et al. ABCG2: a perspective. Adv. Drug Deliv. Rev. 2009;61:3–13
  163. Rojo F, González-Navarrete I, Bragado R, Dalmases A, Menéndez S, Cortes-Sempere M, et al. Mitogen-activated protein kinase phosphatase-1 in human breast cancer independently predicts prognosis and is repressed by doxorubicin. Clin. Cancer Res. 2009;15:3530–3539
  164. Rottenberg S, Nygren AOH, Pajic M, Leeuwen FWB, van der Heijden I, et al. Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer. Proc. Natl. Acad. Sci. U.S.A. 2007;104:12117–12122
  165. Rottenberg S, Jonkers J. Modeling therapy resistance in genetically engineered mouse cancer models. Drug Resist. Updates. 2008;11:51–60
  166. Ruan K, Song G, Ouyang G. Role of hypoxia in the hallmarks of human cancer. J. Cell. Biochem. 2009;
  167. Sahlgren C, Gustafsson MV, Jin S, Poellinger L, Lendahl U. Notch signaling mediates hypoxia-induced tumor cell migration and invasion. Proc. Natl. Acad. Sci. U.S.A. 2008;105:6392–6397
  168. Sainson RCA, Harris AL. Regulation of angiogenesis by homotypic and heterotypic notch signalling in endothelial cells and pericytes: from basic research to potential therapies. Angiogenesis. 2008;11:41–51
  169. Samudio I, Fiegl M, Andreeff M. Mitochondrial uncoupling and the Warburg effect: molecular basis for the reprogramming of cancer cell metabolism. Cancer Res. 2009;69:2163–2166
  170. Sakamoto K, Maeda S, Hikiba Y, et al. Constitutive NF-κB activation in colorectal carcinoma plays a key role in angiogenesis, promoting tumor growth. Clin. Cancer Res. 2009;15:2248–2258
  171. Sartore-Bianchi A, Martini M, Molinari F, et al. PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res. 2009;69:1851–1857
  172. Scotto KW. Transcriptional regulation of ABC drug transporters. Oncogene. 2003;22:7496–7511
  173. See YP, Carlsen SA, Till JE, Ling V. Increased drug permeability in Chinese hamster ovary cells in the presence of cyanide. Biochem. Biophys. Acta. 1974;373:242–252
  174. Sennino B, Kuhnert F, Tabruyn SP, Mancuso MR, Hu-Lowe DD, Kuo CJ, et al. Cellular source and amount of vascular endothelial growth factor and platelet-derived growth factor in tumors determine response to angiogenesis inhibitors. Cancer Res. 2009;69:4527–4536
  175. Shain KH, Yarde DN, Meads MB, et al. β1 integrin adhesion enhances IL-6-mediated STAT3 signaling in myeloma cells: implications for microenvironment influence on tumor cell survival and proliferation. Cancer Res. 2009;69:1009–1015
  176. Shojaei F, Ferrara N. Role of the microenvironment in tumor growth and in refractoriness/resistance to anti-angiogenic therapies. Drug Resist. Updates. 2008;11:219–230
  177. Shojaei F, Wu X, Malik AK, et al. Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+ Gr1+ myeloid cells. Nat. Biotechnol. 2007;25:911–920
  178. Shojaei F, Wu X, Qu X, et al. G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models. Proc. Natl. Acad. Sci. U.S.A. 2009;106:6742–6747
  179. Shukla S, Robey RW, Bates SE, Ambudkar SV. Sunitinib (Sutent, SU11248), a small molecule receptor tyrosine kinase inhibitor, blocks function of the ATP-binding cassette (ABC) transporters P-glycoprotein (ABCB1) and ABCG2. Drug Metab. Dispos. 2009;37:359–365
  180. Sinek JP, Sanga S, Zheng X, Frieboes HB, Ferrari M, Cristini V. Predicting drug pharmacokinetics and effect in vascularized tumors using computer simulation. J. Math. Biol. 2009;58:485–510
  181. Sliwinska MA, Moseniak G, Wolanin K, et al. Induction of senescence with doxorubicin leads to increased genomic instability of HCT116 cells. Mech. Ageing Dev. 2009;130:24–32
  182. Slomiany MG, Dai L, Bomar PA, et al. Abrogating drug resistance in malignant peripheral nerve sheath tumors by disrupting hyaluronan-CD44 interactions with small hyaluronan oligosaccharides. Cancer Res. 2009;69:
  183. Slovak ML, Hoeltge GA, Dalton WS, Trent JM. Pharmacological and biological evidence for differing mechanisms of doxorubicin resistance in two human tumor cell lines. Cancer Res. 1988;48:2793–2797
  184. Sonveaux P, Végran F, Schroeder T, et al. targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. J. Clin. Invest. 2008;118:3930–3942
  185. Stein WD, Litman T, Fojo T, Bates SE. A serial analysis of gene expression (SAGE) database analysis of chemosensitivity: comparing solid tumors with cell lines and comparing solid tumors for drug resistance. Cancer Res. 2004;64:2805–2816
  186. Stein WD, Litman T, Fojo T, Bates SE. Differential expression of cell adhesion genes: implications for drug resistance. Int. J. Cancer. 2005;113:861–865
  187. St.Croix B, Rak JW, Kapitain S, Sheehan C, Graham CH, Kerbel RS. Reversal by hyaluronidase of adhesion-mediated multicellular drug resistance in mammary carcinoma cells. J. Natl. Cancer Inst. 1996;88:1285–1296
  188. Stordal B, Davey R. A systematic review of genes involved in the inverse resistance relationship between cisplatin and paclitaxel chemotherapy: role of BRCA1. Curr. Cancer Drug Targets. 2009;9:354–365
  189. Stumpf MP, Thorne T, de Silva E, et al. Estimating the size of the human interactome. Proc. Natl. Acad. Sci. U.S.A. 2008;105:6959–6964
  190. Sugimura T. Takashi Tsuruo. Mol. Cancer Ther. 2009;8:989–990
  191. Sullivan R, Graham CH. hypoxia prevents etoposide-induced DNA damage in cancer cells through a mechanism involving hypoxia-inducible factor 1. Mol. Cancer Ther. 2009;8:1702–1713
  192. Sullivan R, Paré GC, Frederiksen LJ, Semenza GL, Graham CH. Hypoxia-induced resistance to anticancer drugs is associated with decreased senescence and requires hypoxia-inducible factor-1 activity. Mol. Cancer Ther. 2008;7:1961–1973
  193. Sun RC, Board PG, Blackburn AC. New drug combinations to target the Warburg effect in cancer therapy. In: Proc. of the 100th Ann. Meeting Am. Assoc. Cancer Res.. 2009 April 18–22, Denver, CO/Philadelphia (PA). 2009;Abstract nr 2071
  194. Tabruyn SP, Griffioen AW. NF-κB: a new player in angiostatic therapy. Angiogenesis. 2008;11:101–106
  195. Teicher BA, Herman TS, Holden SA, Wang Y, Pfeffer MR, Crawford JM, et al. Tumor resistance to alkylating agents conferred by mechanisms operative only in vivo. Science. 1990;247:1457–1461
  196. Teicher BA. Hypoxia and drug resistance. Cancer Metast. Rev. 1994;13:139–168
  197. Thomlinson RH, Gray LH. The histological structure of some human lung cancers and the possible implications for radiotherapy. Br. J. Cancer. 1955;9:539–549
  198. Tol J, Koopman M, Cats A, et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. New Engl. J. Med. 2009;360:563–572
  199. Toole BP, Slomiany MG. Hyaluronan, CD44 and Emmprin: partners in cancer cell chemoresistance. Drug Resist. Updates. 2008;11:110–121
  200. Ubezio P, Lupi M, Branduardi D, et al. Quantitative assessment of the complex dynamics of G1, S, and G2-M checkpoint activities. Cancer Res. 2009;69:5234–5240
  201. Van Cruijsen H, van der Veldt AAM, Vroling L, et al. Sunitinib-induced myeloid lineage redistribution in renal cell cancer patients: CD1c+ dendritic cell frequency predicts progression-free survival. Clin. Cancer Res. 2008;14:5884–5892
  202. Van der Heijden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324:1029–1033
  203. Van der Veldt AAM, Boven E, Vroling L, et al. Sunitinib-induced hemoglobin changes are related to the dosing schedule. J. Clin. Oncol. 2009;27:1339–1341
  204. Van Hensbergen Y, Broxterman HJ, Rana S, et al. Reduced growth increased vascular area, and reduced response to cisplatin in CD13-overexpressing human ovarian cancer xenografts. Clin. Cancer Res. 2004;10:1180–1191
  205. Van Wijngaarden J, van Beek E, van Rossum G, et al. Celecoxib enhances doxorubicin-induced cytotoxicity in MDA-MB231 cells by NF-κB-mediated increase of intracellular doxorubicin accumulation. Eur. J. Cancer. 2007;43:433–442
  206. Verheul HMW, Pinedo HM. Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. Nat. Rev. Cancer. 2007;7:475–485
  207. Verheul HMW, Qian DZ, Carducci MA, Pili R. Sequence-dependent antitumor effects of differentiation agents in combination with cell cycle-dependent cytotoxic drugs. Cancer Chemother. Pharmacol. 2007;60:329–339
  208. Versantvoort CHM, Broxterman HJ, Pinedo HM, de Vries EGE, Feller N, Kuiper CM, et al. Energy-dependent processes involved in reduced drug accumulation in multidrug-resistant human lung cancer cell lines without P-glycoprotein expression. Cancer Res. 1992;52:17–23
  209. Vroling L, van der Veldt AAM, de Haas RR, et al. Increased numbers of small circulating endothelial cells in renal cell cancer patients treated with sunitinib. Angiogenesis. 2009;12:69–79
  210. Wallin J, Edgar K, Guan J, Friedman L, Belvin M. Transient pAkt increase after chemo exposure predicts strength of synergy for combinations of the PI3K inhibitor GDC-0941 and chemotherapeutics. In: Proc. of the 100th Ann. Meeting Am. Assoc. Cancer Res.. 2009 April 18–22, Denver, CO/Philadelphia (PA). 2009;Abstract nr 3392
  211. Wang F, Liu R, Lee SW, Sloss CM, Couget J, Cusack JC. Heparin-binding EGF-like growth factor is an early response gene to chemotherapy and contributes to chemotherapy resistance. Oncogene. 2007;26:2006–2016
  212. Warburg O. On the origin of cancer cells. Science. 1956;123:309–314
  213. Warburg O, Posener K, Negelein E. Űber den Stoffwechsel der Tumoren. Biochem. Z. 1924;152:319–344
  214. Weisenthal LM, Patel N, Rueff-Weisenthal C. Cell culture detection of microvascular cell death in clinical specimens of human neoplasms and peripheral blood. J. Intern. Med. 2008;264:275–287
  215. Wielinga PR, Westerhoff HV, Lankelma J. The relative importance of passive and P-glycoprotein mediated anthracycline efflux from multidrug resistant cells. Eur. J. Biochem. 2000;267:649–657
  216. Will Y, Dykens JA, Nadanaciva S, et al. Effect of multitargeted tyrosine kinase inhibitors imanitinb, dasatinib, sunitinib, and sorafenib on mitochondrial function in isolated rat heart mitochondria and H9c2 cells. Toxicol. Sci. 2008;106:153–161
  217. Williams BR, Amon A. Aneuploidy: cancer's fatal flaw?. Cancer Res. 2009;69:5289–5291
  218. Williams RT, den Besten W, Sherr CJ. Cytokine-dependent imatinib resistance in mouse BCR-ABL+, Arf-null lymphoblastic leukemia. Genes Dev. 2007;21:2283–2287
  219. Wouters BG, Koritzinsky M. Hypoxia signaling through mTOR and the unfolded protein response in cancer. Nat. Rev. Cancer. 2008;8:851–864
  220. Xie H, Valera VA, Merino MJ. LDH-A inhibition, a therapeutic strategy for treatment of hereditary leiomyomatosis and renal cell cancer. Mol. Cancer Ther. 2009;8:626–635
  221. Xin H, Zhang C, Herrmann A, Du Y, Figlin R, Yu H. Sunitinib inhibition of STAT3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells. Cancer Res. 2009;69:2506–2513
  222. Yan M, Plowman GD. Delta-like 4/Notch signaling and its therapeutic implications. Clin. Cancer Res. 2007;13:7243–7246
  223. Yee KW, Schittenheim M, O’Farrell A, et al. Synergistic effect of SU11248 with cytarabine or daunorubicin on FLT3-ITD positive leukemic cells. Blood. 2004;104:4202–4209
  224. Yeh GC, Occhipinti SJ, Cowan KH, Chabner BA, Myers CE. Adriamycin resistance in human tumor cells associated with marked alterations in the regulation of the hexose monophosphate shunt and its response to oxidant stress. Cancer Res. 1987;47:5994–5999
  225. Yoon J, Deisboeck TS. Investigating differential dynamics of the MAPK signaling cascade using a multi-parametric global sensitivity analysis. PLOS one. 2009;4:e4560
  226. Yu Y, Anjum R, Kubota K, Rush J, Villen J, Gygi SP. A site-specifc, multiplexed kinase activity assay using stable-isotope dilution and high-resolution mass spectrometry. Proc. Natl. Acad. Sci. U.S.A. 2009;
  227. Yu L, Wu WKK, Li ZJ, et al. Enhancement of doxorubicin cytotoxicity on human esophageal squamous cell carcinoma cells by indomethacin and 4-[5-(4-chrlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (SC236) via inhibiting P-glycoprotein. Mol. Pharmacol. 2009;75:1364–1373
  228. Yun CH, Mengwasser KE, Toms AV, et al. The T790 M mutation in EGR kinase causes drug resistance by increasing the affinity for ATP. Proc. Natl. Acad. Sci. U.S.A. 2008;105:2070–2075
  229. Zhang WW, Cortes JE, Yao H, et al. Predictors of primary imatinib resistance in chronic myelogenous leukemia are distinct from those in secondary imatinib resistance. J. Clin. Oncol. 2009;
  230. Zhong D, Xiong L, Liu T, et al. The glycolytic inhibitor 2-deoxyglucose activates multiple prosurvival pathways through IGF1R. J. Biol. Chem. 2009;
  231. Zhou QY, Gallo JM. Differential effect of sunitinib on the distribution of temozolomide in an orthotopic glioma model. Neuro-Oncology. 2009;11:301–310
  232. Zhou Q, Guo P, Gallo JM. Impact of angiogenesis inhibition by sunitinib on tumor distribution of temozolomide. Clin. Cancer Res. 2008;14:1540–1549
  233. Zong WX, Ditsworth D, Bauer DE, Wang ZQ, Thompson CB. Alkylating DNA damage stimulates a regulated form of necrotic cell death. Genes Dev. 2004;18:1272–1282
  234. Zunder ER, Knight ZA, Houseman BT, Apsel B, Shokat KM. Discovery of drug-resistant and drug-sensitizing mutations in the oncogenic PI3K isoform p110α. Cancer Cell. 2008;14:180–192

PII: S1368-7646(09)00048-X

doi: 10.1016/j.drup.2009.07.001

Drug Resistance Updates
Volume 12, Issue 4 , Pages 114-126 , August 2009

Article Tools